The tweet was deleted by the author.
But we saved everything 🙂.
Tyra Biosciences has launched the SURF302 clinical trial to assess a novel therapeutic strategy targeting intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC).
The study aims to address major treatment challenges associated with this type of bladder cancer, focusing on improving patient management and outcomes. The company is seeking to find new solutions to persistent obstacles in IR-NMIBC care, with further details about the trial available on its official website.
View post on X Loading...
Tyra Biosciences recently intensified efforts to develop new therapies for urologic cancers, collaborating with experts and advocates as part of its research initiatives, as reported in a prior update. Earlier findings from the company linked FGFR3 gene changes to various cell growth disorders, affecting bone development and certain urologic cancers, according to company data. These prior studies contribute to the context for the current SURF302 clinical trial.